| Literature DB >> 31809296 |
Thomas Chateau1,2, Roger Feakins3, Aude Marchal-Bressenot4, Fernando Magro5,6,7, Silvio Danese8, Laurent Peyrin-Biroulet2.
Abstract
In recent years, the therapeutic goals in ulcerative colitis (UC) have become increasingly stringent. Histological features seem to be a reliable predictor of disease outcomes after therapy, and histological remission (HR) is the new frontier in the treatment of UC. Here, we first provide a historical perspective before reviewing indexes in the era of biologics; histology as a treatment goal in UC trials; the poor correlation between symptoms, endoscopy, and histology; and the impact of histology on disease outcomes. HR seems to be a promising end point for the treatment of UC because it is typically associated with better outcomes. Two new validated indexes are available to assess histology more accurately in trials, and they may also be applicable to clinical practice. Additional interventional trials are now necessary to establish definitions of HR and its potential for disease modification.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31809296 DOI: 10.14309/ajg.0000000000000437
Source DB: PubMed Journal: Am J Gastroenterol ISSN: 0002-9270 Impact factor: 10.864